levofloxacin / Generic mfg. - LARVOL DELTA

Real-World Experience with Teclistamab and Talquetamab Combination Therapy in Relapsed/Refractory Multiple Myeloma (IMS 2026) - "Introduction: Combination therapy with teclistamab and talquetamab (tec/tal) is an effective option for patients with relapsed/refractory multiple myeloma (Cohen et al., NEJM 2025). In this single-center real-world experience study with tec/tal, no new safety signals were identified among a heavily pretreated cohort of patients despite poor PS and presence of EMD. Surprisingly, when taken in the context of tec/tal clinical trial data, no infectious complications were observed. The lack of infections may reflect improved infectious prophylaxis with IVIG independent of IgG levels and levofloxacin for all patients for at least one month."

Clinical • Combination therapy • Real-world • Real-world evidence • Hematological Malignancies • Infectious Disease • Multiple Myeloma

Early Infectious Complications and Hypogammaglobulinaemia in Patients Receiving Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma: A Single-Centre Real-World Experience (IMS 2026) - "All patients received standard antiviral and Pneumocystis prophylaxis, with levofloxacin reserved for selected high-risk patients... Twenty-four patients received BsAb therapy: elranatamab (n=17, 70.8%), teclistamab (n=4, 16.7%), talquetamab (n=3, 12.5%)... This real-world cohort demonstrates a substantial early infectious burden associated with BsAb therapy, with infections occurring from cycle 1 in nearly half of patients despite widespread IVIG use and routine antimicrobial prophylaxis. Both bacterial and viral pathogens contributed significantly to morbidity, and all CMV reactivations occurred in patients receiving BCMA-targeting therapy. No infection-attributable mortality was observed."

Bispecific • Clinical • Real-world • Real-world evidence • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Inflammation • Influenza • Multiple Myeloma • Otorhinolaryngology • Respiratory Diseases • Sinusitis • AVEN

IDENTIFICATION AND PRECLINICAL EVALUATION OF 2-METHOXY-1,4-NAPHTHOQUINONE AS A NOVEL NON-ANTIBIOTIC AGENT FOR ERADICATING HELICOBACTER PYLORI: FROM HIGH-THROUGHPUT SCREENING TO IN VIVO VALIDATION (UEGW 2026) - "First, a high-throughput screen of 1,905 traditional Chinese medicine monomers was performed using multidrug-resistant clinical isolates, including a levofloxacin- and metronidazole-resistant strain (#5148)... MNQ represents a promising non-antibiotic therapeutic candidate for eradicating multidrug-resistant H. pylori. By targeting respiratory chain complex I and inducing metabolic collapse without detectable host toxicity or disrupting host microbiota, MNQ provides strong preclinical support for the development of next-generation eradication strategies against antibiotic-resistant H. pylori."

Preclinical • Gastric Cancer • Infectious Disease • Solid Tumor • Targeted Protein Degradation

EFFECTIVENESS OF FIRST-LINE EMPIRICAL HELICOBACTER PYLORI TREATMENT OUTSIDE EUROPE: RESULTS OF 15,000 CASES FROM THE WORLD-WIDE REGISTRY ON H. PYLORI MANAGEMENT (WORLDHPREG) (UEGW 2026) - "Overall effectiveness was 86%, reaching approximately 90% with bismuth-based quadruple therapies including: amoxicillin-levofloxacin (96%; OR 4.82; 95% CI 3.2–7.27); metronidazole-tetracycline, either as a single-capsule formulation (94%; OR 7.66; 4.93–11.91) or as a traditional regimen (89%; OR 2.32; 1.48–3.36); amoxicillin-metronidazole (94%; OR 3.52; 2.18–5.68); and amoxicillin-doxycycline (97%; OR 8.02; 3.26–19.7). Outside Europe, most bismuth-based quadruple therapies achieve ≥90% effectiveness, whereas dual amoxicillin therapy and concomitant quadruple therapy with amoxicillin-clarithromycin-metronidazole do so only in specific regions. Adherence, treatment duration of ≥10–14 days, and the use of PCABs are associated with higher eradication success."

Clinical • Infectious Disease

HELICOBACTER PYLORI ANTIBIOTIC SUSCEPTIBILITY, ERADICATION THERAPY PRESCRIPTION AND DISPENSATION PATTERNS IN CENTRAL NORWAY (UEGW 2026) - "and omeprazole 40 mg b.i.d...After patient consent susceptibility testing of 306 isolates for amoxicillin, clarithromycin, levofloxacin, tetracycline by agar gradient diffusion method and of 234 isolates, still viable after freezing, for metronidazole by agar dilution method using H. pylori ATCC 43504 strain as control... Resistance to metronidazole is common in both previously untreated and treated patients. The national standard course for empiric H pylori treatment which includes metronidazole, may be insufficient to achieve eradication in a substantial proportion of patients."

Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Solid Tumor

INFLUENCE OF ETHNICITY ON HELICOBACTER PYLORI ERADICATION THERAPY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORIMANAGEMENT (HP-EUREG) (UEGW 2026) - "Overall, clarithromycin-based triple therapy (amoxicillin/metronidazole) was the most frequently used first-line regimen, whereas bismuth-based quadruple therapy (metronidazole-tetracycline) was the most common rescue regimen.Both bismuth and non-bismuth quadruple therapies showed the highest effectiveness as first-line regimens, particularly concomitant quadruple therapy (clarithromycin-amoxicillin-metronidazole/tinidazole), bismuth quadruple therapy with metronidazole-tetracycline, and bismuth quadruple therapy with clarithromycin-amoxicillin. However, bismuth-based quadruple therapy with metronidazole-tetracycline and bismuth-based quadruple therapy with levofloxacin-amoxicillin achieved the highest eradication rates as rescue regimens... In Europe, significant differences were observed across ethnic groups in the prescription, effectiveness, and tolerability of H. pylori eradication therapies. Asian patients were more frequently treated with bismuth-containing..."

Infectious Disease

EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE: DATA FROM 10,000 CASES FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "After failure of first-line clarithromycin-containing therapy, the most effective therapies were triple therapy with amoxicillin plus either rifabutin or levofloxacin, achieving 84% and 81% effectiveness by mITT, respectively. Additionally, bismuth quadruple therapy with tetracycline-metronidazole (either as single-capsule or classical formulation), clarithromycin-amoxicillin and levofloxacin-amoxicillin achieved 88%, 86%, 88% and 86% cure rates by mITT, respectively... In Europe, the overall effectiveness of empirical second-line treatment is suboptimal. These findings highlight the need for improved treatment strategies and support the use of optimised approaches after first-line failure."

Clinical • Dyspepsia • Immunology • Infectious Disease • Peptic Ulcer

HELICOBACTER PYLORI RESCUE THERAPY GUIDED BY FECAL MOLECULAR RESISTANCE DETECTION: A PILOT STUDY (UEGW 2026) - "Resistance to clarithromycin, amoxicillin, metronidazole, levofloxacin, and tetracycline was assessed using a high-resolution melting curve, by analysing, respectively, 23SrRNA, pbp1, frrxA/rdxA, gyrA and 16SrRNA. Investigating H. pylori antibiotic resistance on stool samples may efficiently guide choice of the treatment in patients with previous failures. Our study pointed out that even a suboptimal regimen like triple may be efficient in case of favourable resistance profile. Future studies will ascertain whether this strategy may be superior to empirical rescue therapy."

Clinical • Infectious Disease

EXPERIENCE WITH RIFABUTIN-CONTAINING THERAPY IN 900 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "Culture results were available in 62% of patients, showing dual resistance (clarithromycin and metronidazole) in 43%, and triple resistance (clarithromycin, metronidazole, and levofloxacin) in 36%. Rifabutin-containing regimens represent an effective and generally safe rescue option even after multiple prior treatment failures for H. pylori eradication, although there is still room for improvement."

Clinical • Dyspepsia • Gastroenterology • Hematological Disorders • Infectious Disease • Leukopenia • Peptic Ulcer • Thrombocytopenia

HELICOBACTER PYLORI EMPIRICAL FIRST-LINE AND RESCUE TREATMENT EFFECTIVENESS IN PATIENTS ALLERGIC TO PENICILLIN: EXPERIENCE AMONG 2,700 CASES OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "However, bismuth quadruple therapy with tetracycline-metronidazole, either as a single-capsule formulation (Pylera®) or as a traditional regimen (Quad-MTcB), is increasingly recommended...In second-line therapy, the most commonly used regimens were the single-capsule (29%), and triple therapies with clarithromycin-levofloxacin (16%), and with metronidazole-levofloxacin (10%), showing heterogeneous effectiveness (86%, 74%, and 67%, respectively; p<0.01), generally lower than in first-line therapy but remaining high for bismuth-based quadruple therapies... In patients allergic to penicillin, Triple-CM should not be used as first-line therapy due to its lower effectiveness compared with bismuth quadruple regimens. Bismuth quadruple therapy, particularly with the single-capsule formulation, achieves high eradication rates and is the preferred first-line option. Treatment effectiveness decreases in subsequent lines, with bismuth-based quadruple regimens remaining the..."

Clinical • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Peptic Ulcer

SAFETY OF HELICOBACTER PYLORI ERADICATION THERAPIES: AN ANALYSIS OF 59,000 PATIENTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "The regimen associated with the highest incidence of AEs was the triple therapy with amoxicillin-metronidazole (33%), whereas the lowest incidence was observed with the triple therapy with clarithromycin-levofloxacin and with the quadruple therapy with clarithromycin-metronidazole-bismuth (11% each). AEs during H. pylori eradication therapy, although frequent, are generally mild and transient and do not interfere with treatment adherence."

Clinical • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Solid Tumor

OPTIMUM SECOND-LINE REGIMENS FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF A SYSTEMATIC REVIEW WITH META-ANALYSIS (UEGW 2026) - "Classical B quadruple therapy, with proton pump inhibitor (PPI)-metronidazole (M)- tetracycline (Tc), outperformed multiple comparators, including clarithromycin (C)-based and non-B regimens. Tc-containing therapies generally surpassed levofloxacin (L)-based regimens in direct comparisons, while L-based and some simplified regimens were associated with lower eradication rates. Following PPI-amoxicillin (A)-C triple therapy failure, PPI-B-M-Tc was significantly more effective than PPI-L-M triple therapy (RD=-0.16, 95%CI: -0.32, -0.01), and PPI-B-C-M quadruple therapy (RD=0.25, 95%CI: 0.07, 0.43)...Additionally, RBC-M-Tc triple therapy was superior to RBC-azithromycin dual therapy (RD=-0.32, 95%CI: -0.55, -0.10) and to PPI+B+M+Tc quadruple therapy (RD=-0.30, 95%CI: -0.52, -0.09)... The efficacy of second-line H. pylori therapies varies substantially depending on the initial regimen. B-based quadruple therapies, particularly PPI+B+M+Tc, were consistently the most effective..."

Retrospective data • Review • Infectious Disease

EFFECTIVENESS AND SAFETY OF EMPIRICAL HELICOBACTER PYLORI TREATMENT IN POLAND: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "The most frequently used regimens, accounting for 78% of the treatments overall, were bismuth-based quadruple therapies, administered either as a single-capsule formulation or prescribing drugs (metronidazole + tetracycline + bismuth) separately...Although higher eradication rates (>90%) were observed in selected 14-day regimens (e.g., bismuth quadruple or amoxicillin–levofloxacin triple therapy), these findings were based on very small patient numbers (n=2–3).Treatment adherence was high, with 98% of patients taking ≥90% of the prescribed drugs... In Polish routine clinical practice, first-line effectiveness approached but did not consistently reach 90%, while second-line therapies remained below this threshold. The highest effectiveness was achieved with bismuth-based quadruple regimens administered for 10–14 days. High-dose PPIs enhanced the effectiveness of first-line triple therapy with amoxicillin and metronidazole, but not in quadruple therapy."

Clinical • Gastric Cancer • Infectious Disease • Solid Tumor

SEQUENTIAL THERAPY OUTPERFORMS STANDARD TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A PROSPECTIVE REAL-WORLD COMPARISON OF VONOPRAZAN AND PROTON PUMP INHIBITORS (UEGW 2026) - "Patients with significant comorbidities or prior inadvertent PPI use were excluded.Participants were randomized into four treatment strategies (A–D), each subdivided into PPI-based (A1–D1) and vonoprazan-based (A2–D2) arms (n=25 per subgroup):A: Amoxicillin + ClarithromycinB: Amoxicillin + LevofloxacinC: Sequential (Amoxicillin → Clarithromycin + Tinidazole)D: Sequential (Amoxicillin → Levofloxacin + Tinidazole)Eradication was confirmed using stool antigen testing. Sequential therapy, particularly levofloxacin-based, provides superior eradication outcomes compared to standard triple therapy in routine outpatient practice.Vonoprazan offers incremental benefit over PPI-based regimens, supporting its role in optimized eradication strategies.A strategy-driven approach focusing on regimen selection and adherence is essential to improving H. pylori treatment success."

Clinical • Real-world • Real-world evidence • Infectious Disease

HIGH ANTIMICROBIAL RESISTANCE RATES IN HELICOBACTER PYLORI ISOLATES FROM A COLOMBIAN UNIVERSITY HOSPITAL: A RETROSPECTIVE CULTURE-BASED STUDY (UEGW 2026) - "This large single-centre Latin American culture-based series demonstrates a high burden of resistance to metronidazole, levofloxacin, and clarithromycin, together with substantial multidrug resistance. Clarithromycin and levofloxacin resistance were both well above thresholds commonly considered incompatible with empiric use. In contrast, resistance to amoxicillin and tetracycline remained uncommon."

Retrospective data • Gastric Cancer • Infectious Disease • Solid Tumor

PRESCRIPTION OF FIRST-LINE EMPIRICAL TREATMENTS FOR HELICOBACTER PYLORI INFECTION OUTSIDE EUROPE: RESULTS OF 15,000 CASES FROM THE WORLD-WIDE REGISTRY ON H. PYLORI MANAGEMENT (WORLDHPREG) (UEGW 2026) - "Other regimens included triple therapy with PPI-amoxicillin-levofloxacin (9.1%) and dual therapy with PPI-amoxicillin (8.1%). The WorldHpReg demonstrates marked regional heterogeneity in first-line H. pylori therapies, with predominance of standard triple therapy with PPI-amoxicillin-clarithromycin and limited use of quadruple regimens, highlighting the need for local treatment protocols to improve eradication rates."

Clinical • Dyspepsia • Gastroenterology • Infectious Disease

THE RELEVANCE OF LIVER BIOPSY IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS AND CHOLESTASIS: A CASE OF HEPATIC TUBERCULOSIS MIMICKING DRUG-INDUCED LIVER INJURY (UEGW 2026) - "Suspected drug-induced liver injury (DILI) prompted a switch to amikacin, levofloxacin, ethambutol, and meropenem...The patient was discharged on levofloxacin, rifampicin, isoniazid, and ethambutol, in addition to prednisone, ART, and standard treatment for neurotoxoplasmosis.Two months later, he was readmitted with vomiting and jaundice...Microscopy for acid-fast bacilli was negative, but the Xpert MTB/RIF confirmed hepatic tuberculosis and rifampicin resistance.A multidrug-resistant tuberculosis regimen was initiated (levofloxacin, clofazimine, bedaquiline, and terizidone) leading to an 80% reduction in alkaline phosphatase and normalization of serum bilirubin within three months.This case highlights the challenge of distinguishing DILI from opportunistic infections in advanced HIV, particularly in cholestatic presentations with hepatotoxic drug exposure. Noninvasive tests may be insufficient, emphasizing the role of liver biopsy and molecular testing in management."

Biopsy • Clinical • Cholestasis • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Failure • Respiratory Diseases • Septic Shock • Tuberculosis

Increased Prevalence of Multidrug-Resistant Escherichia coli as an Adverse Effect of Excessive Antibiotic Use in a Tertiary Care Hospital in Serbia. (PubMed, Life (Basel)) - "Total antibiotic consumption remained stable, with no correlation between consumption and MDR isolation rates, although ampicillin resistance increased significantly. Compared with 2015, resistance significantly increased to amoxicillin-clavulanic acid, cefotaxime, cefepime, ceftazidime, ciprofloxacin, and levofloxacin, while ceftriaxone resistance decreased. The blaCTX-M gene was detected in 53% of bloodstream isolates, indicating widespread dissemination of ESBL-producing E. coli and highlighting the need for continuous surveillance and antimicrobial stewardship."

Adverse events • Journal • Infectious Disease

Occurrence and Antimicrobial Resistance Profiles of Culturable Ampicillin-Resistant Gram-Negative Bacteria in the Ring of Cenotes Aquifer, Yucatán, Mexico. (PubMed, Microorganisms) - "Resistance to cefotaxime, levofloxacin, gentamicin, and tetracycline was detected among several bacterial genera. Genomic analysis of 19 E. coli isolates revealed resistance determinants associated with multiple antimicrobial classes and a diverse population structure dominated by phylogroup B1. These findings show that the Ring of Cenotes aquifer harbors diverse populations of culturable ampicillin-resistant Gram-negative bacteria and emphasize the importance of groundwater ecosystems as environmental reservoirs of AMR."

Journal • Infectious Disease • Pneumonia

Microbacterium paraoxydans Bloodstream Infection in a Patient with Long-Term Indwelling Central Venous Catheter: A Case Report and Literature Review. (PubMed, Microorganisms) - "After the chemo port was removed, vancomycin followed by levofloxacin was administered for the entire 14-day treatment course according to susceptibility tests...is not fully characterized and varies across reports; gentamicin and trimethoprim/sulfamethoxazole appeared more consistently active, whereas susceptibility to vancomycin was variable. We report this case to highlight the increasing number of infections caused by Microbacterium spp. in the current era and to provide information on the treatment of M. paraoxydans."

Journal • Dermatology • Esophageal Cancer • Immunology • Infectious Disease • Oncology • Psoriasis

Antibiotic Selection for Sustained Local Therapy May Be Important to Reduce Pseudomonas aeruginosa Dominance Against Staphylococcus aureus and Bone Response Modulation in an Ovine Polymicrobial Fracture-Related Infection Model. (PubMed, Microorganisms) - "A systemic levofloxacin plus rifampin regimen more effectively reduced S. aureus than P. aeruginosa. These findings indicate that microbiological burden reduction, residual pathogen composition, and bone preservation may result in distinct treatment outcomes in polymicrobial FRI. This study highlights the need for appropriate antibiotic selection with ecologically informed, dual targeted local and systemic strategies to manage polymicrobial, biofilm-complicated FRIs."

Journal • Infectious Disease • Musculoskeletal Diseases • Orthopedics

TAPB-DHTP functionalized cotton fiber for in-syringe solid-phase extraction and determination of fluoroquinolones in food samples. (PubMed, J Chromatogr A) - "After coupling with ultra-performance liquid chromatography, the method was used for the determination of enoxacin, levofloxacin, and ciprofloxacin. The method was applied to honey, egg white, and fish samples, giving recoveries of 81.05-97.23% with RSDs below 9.77%. The results demonstrate that TAPB-DHTP COF@cotton provides a practical fibrous adsorbent for trace fluoroquinolone determination in complex food matrices."

Journal

Conjunctival reactive cutaneous capillary endothelial proliferation induced by camrelizumab in an esophageal cancer patient: a case report and literature review. (PubMed, Front Oncol) - "Unlike previously reported eyelid lesions requiring excision, conservative management with topical levofloxacin resulted in complete lesion resolution within four weeks without discontinuation of systemic therapy (Naranjo score: 7). This represents the first documented case of RCCEP affecting the conjunctival mucosa. It underscores the necessity of ophthalmologic surveillance in patients receiving camrelizumab and demonstrates that topical antimicrobial therapy constitutes an effective therapeutic strategy for complicated ocular RCCEP."

Journal • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Infectious Disease • Oncology • Ophthalmology • Squamous Cell Carcinoma

Agent-Specific Clinical Profiles of Antibiotic-Associated Encephalopathy: A Dual-Database Pharmacovigilance Study Using JADER and FAERS. (PubMed, Antibiotics (Basel)) - " Using the Japanese Adverse Drug Event Report (JADER) database and the US FDA Adverse Event Reporting System (FAERS, 2004-2026), we studied metronidazole, cefepime, ceftriaxone, ceftazidime, and levofloxacin. AAE is reported not as a single uniform event but with profiles specific to the causative antibiotic. Awareness of these agent-specific patterns may support earlier recognition, although confirmation in analytic studies with exposure denominators is warranted."

Adverse events • Journal • Ataxia • CNS Disorders • Movement Disorders

Antibiotic Utilization Patterns and Appropriateness of Antibiotic Prescribing in an Internal Medicine Service of a Secondary Care Hospital: A Retrospective Drug Utilization Study. (PubMed, Antibiotics (Basel)) - "High overall guideline alignment (73%) coexisted with substantial use of broad-spectrum antimicrobials. Stewardship prioritization should integrate quantitative utilization with qualitative prescribing assessment rather than interpret total DDD burden as avoidable exposure. These findings provide a baseline for targeted antimicrobial stewardship and clinical-pharmacy interventions in a resource-constrained secondary-care setting."

Journal • Retrospective data